MeLysine-Stapling: Stabilized Oncolytic Peptide Efficacy Data

5.6 KB of data from a study validating a novel 'MeLysine-stapling' strategy for engineering stable peptide therapeutics. The lead candidate MeLS-5 exhibited a serum half-life exceeding 48 hours and demonstrated a geometric mean IC50 of 3.9 μM across nine cancer cell lines. The dataset, authored by Lei Xu and last updated in May 2026, contains results from in vitro and in vivo experiments, including a syngeneic 4T1 xenograft model.

Use Cases

• Analyzing the relationship between peptide modification strategies and serum stability based on the described half-life data.
• Comparing the broad-spectrum cytotoxicity of stabilized peptides across different cancer cell lines based on the reported IC50 values.
• Evaluating the in vivo antitumor efficacy and safety profile of oncolytic peptides based on the described xenograft model results.
• Benchmarking novel peptide stabilization methods against the reported MeLysine-stapling strategy.

Strengths

• Includes specific, quantitative results such as a 32-fold increase in serum half-life and a geometric mean IC50 of 3.9 μM.
• Reports in vivo efficacy data, showing 63% tumor growth inhibition in a 4T1 xenograft model at a defined dosage (5 mg/kg).
• Data is associated with a clearly defined, novel chemical strategy (MeLysine-stapling with N-terminal acetylation).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The 5.6 KB size suggests a very limited scope, likely containing summary results rather than raw experimental data.

Provenance

Source

figshare

Collection Method

Likely contains experimental results from peptide synthesis, in vitro cytotoxicity assays, and in vivo mouse model studies.

Freshness

Last updated 2026-05-19 10:31:48; freshness should be verified.